**1. Name of the medicinal product**

**1.1. Name of the medicinal product:**

**Generic Name/INN Name:** Ciprofloxacin Tablets USP 500 mg

**Trade Name:** Generic

**1.2 Strength:**

Each film coated tablet contains:

Ciprofloxacin Hydrochloride USP

eq. to Ciprofloxacin base 500 mg

Excipients q.s.

Colour: Titanium Dioxide

**1.3 Pharmaceutical form:**

Solid Oral Dosage form – Tablets

**2. Qualitative and Quantitative composition:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sr.**  **No.** | **Ingredients** | **Label Claim**  **(mg)** | **Actual Qty./Tablet (mg)** | **%w/w** | **Function** |
| **Dry Mixing** | | | | | |
| 1. | Ciprofloxacin Hydrochloride USP\* Eq. to Ciprofloxacin | 500.00 | 582.000 | 90.233 | Active |
| 2. | Microcrystalline Cellulose BP \*\* | ---- | 8.000 | 1.240 | Diluent |
| **Binding** | | | | | |
| 3. | Maize Starch BP | ---- | 7.500 | 1.163 | Binder |
| 4. | Povidone K-30 BP | ---- | 2.000 | 0.310 | Binder |
| 5. | Methyl Hydroxybenzoate BP | ---- | 0.400 | 0.062 | Preservative |
| 6. | Propyl Hydroxybenzoate BP | ---- | 0.100 | 0.016 | Preservative |
| 7. | Purified Water \*\*\* | ---- | 125.000 | --- | Solvent |
| **Blending & Lubrication** | | | | | |
| 8. | Purified Talc BP | ---- | 10.000 | 1.550 | Glidant |
| 9. | Magnesium Stearate BP | ---- | 5.000 | 0.775 | Lubricant |
| 10. | Croscarmellose Sodium BP | ---- | 5.000 | 0.775 | Disintegrant |
| 11. | Kyron T-314 IH | ---- | 5.000 | 0.775 | Superfast disintegrant/Dissolution improver |
| 12. | Colloidal Anhydrous Silica BP | ---- | 2.500 | 0.388 | Lubricant |
| 13. | Sodium Starch Glycolate BP | ---- | 2.500 | 0.388 | Disintegrant |
| **Total Weight of Uncoated Tablet** | | | **630.000 mg** |  |  |
| **Film Coating** | | | | | |
| 14. | Dichloromethane\*\*\*\* BP | ---- | 42.750 | ---- | Solvent |
| 15. | Isopropyl Alcohol\*\*\*\* BP | ---- | 28.500 | ---- | Solvent |
| 16. | Hydroxypropyl Methylcellulose-E-15 BP | ---- | 3.750 | 0.581 | Coating Agent/Dissolution enhancer |
| 17. | Purified Talc BP | ---- | 0.875 | 0.136 | Glidant |
| 18. | Titanium Dioxide BP | ---- | 0.375 | 0.058 | Colorant |
| 19. | Purified Water BP \*\*\*\* | ---- | 60.000 | --- | Solvent |
| 20. | Instacoat Aqua III  (IA-III 40001-White) IH | ---- | 10.000 | 1.550 | Film former |
| **Total Weight of Film Coated Tablet** | | | **645.000 mg** | 100.000 |  |

**Note:**

\* The quantity of the Ciprofloxacin Hydrochloride has to be calculated as per the Assay & LOD.

\*\* Quantity of Microcrystalline Cellulose will vary as per the quantity of the APIs.

\*\*\*The materials that will not remain in the final product.

**3. Pharmaceutical form:**

**Dosage Form:** Solid Oral Dosage form - Tablets

**Visual & Physical characteristics of the product:**

A white colour, capsule shape, biconvex, film coated tablets having break line on one side and plain on other side of the tablets.

**4. Clinical particulars**

**4.1. Therapeutic indications:**

Ciprofloxacin film-coated tablets are indicated for the treatment of the following infections. Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Adults

• Lower respiratory tract infections due to Gram-negative bacteria

- pneumonia

- exacerbations of chronic obstructive pulmonary disease

- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis

• Chronic suppurative otitis media

• Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria

• Urinary tract infections

• Gonococcal uretritis and cervicitis

• Epididymo-orchitis including cases due to Neisseria gonorrhoeae

• Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae

In the above genital tract infections when thought or known to be due to Neisseria gonorrhoeae it is particularly important to obtain local information on the prevalence of resistance to ciprofloxacin and to confirm susceptibility based on laboratory testing.

• Infections of the gastro-intestinal tract (e.g. travellers' diarrhoea)

• Intra-abdominal infections

• Infections of the skin and soft tissue caused by Gram-negative bacteria

• Malignant external otitis

• Infections of the bones and joints

• Treatment of infections in neutropenic patients

• Prophylaxis of infections in neutropenic patients

• Prophylaxis of invasive infections due to Neisseria meningitidis

• Inhalation anthrax (post-exposure prophylaxis and curative treatment)

Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Children and adolescents

• Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa

• Complicated urinary tract infections and pyelonephritis

• Inhalation anthrax (post-exposure prophylaxis and curative treatment)

Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.

Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.

**4.2 Posology and method of administration:**

Posology

The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.

The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.

Treatment of infections due to certain bacteria (e.g. Pseudomonas aeruginosa, Acinetobacter or Staphylococci) may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.

Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.

Adults

|  |  |  |  |
| --- | --- | --- | --- |
| **Indications** | | **Daily dose in mg** | **Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)** |
| Infections of the lower respiratory tract | | 500 mg twice daily to 750 mg twice daily | 7 to 14 days |
| Infections of the upper respiratory tract | Acute exacerbation of chronic sinusitis | 500 mg twice daily to 750 mg twice daily | 7 to 14 days |
| Chronic suppurative otitis media | 500 mg twice daily to 750 mg twice daily | 7 to 14 days |
| Malignant external otitis | 750 mg twice daily | 28 days up to 3 months |
| Urinary tract infections | Uncomplicated cystitis | 250 mg twice daily to 500 mg twice daily | 3 days |
| In pre-menopausal women, 500 mg single dose may be used | |
| Complicated cystitis, Uncomplicated pyelonephritis | 500 mg twice daily | 7 days |
| Complicated pyelonephritis | 500 mg twice daily to 750 mg twice daily | at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses) |
| Prostatitis | 500 mg twice daily to 750 mg twice daily | 2 to 4 weeks (acute) to 4 to 6 weeks (chronic) |
| Genital tract infections | Gonococcal uretritis and cervicitis | 500 mg as a single dose | 1 day (single dose) |
| Epididymo-orchitis and pelvic inflammatory diseases | 500 mg twice daily to 750 mg twice daily | at least 14 days |
| Infections of the gastro-intestinal tract and intraabdominal infections | Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers' diarrhoea | 500 mg twice daily | 1 day |
| Diarrhoea caused by Shigella dysenteriae type 1 | 500 mg twice daily | 5 days |
| Diarrhoea caused by Vibrio cholerae | 500 mg twice daily | 3 days |
| Typhoid fever | 500 mg twice daily | 7 days |
| Intra-abdominal infections due to Gram-negative bacteria | 500 mg twice daily to 750 mg twice daily | 5 to 14 days |
| Infections of the skin and soft tissue | | 500 mg twice daily to 750 mg twice daily | 7 to 14 days |
| Bone and joint infections | | 500 mg twice daily to 750 mg twice daily | max. of 3 months |
| Treatment of infections or prophylaxis of infections in neutropenic patients Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance. | | 500 mg twice daily to 750 mg twice daily | Therapy should be continued over the entire period of neutropenia |
| Prophylaxis of invasive infections due to Neisseria meningitides | | 500 mg as a single dose | 1 day (single dose) |
| Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.  Drug administration should begin as soon as possible after suspected or confirmed exposure. | | 500 mg twice daily | 60 days from the confirmation of Bacillus anthracis exposure |

Children and adolescents

|  |  |  |
| --- | --- | --- |
| **Indications** | **Daily dose in mg** | **Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)** |
| Cystic fibrosis | 20 mg/kg body weight twice daily with a maximum of 750 mg per dose. | 10 to 14 days |
| Complicated urinary tract infections and pyelonephritis | 10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose. | 10 to 21 days |
| Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure. | 10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose. | 60 days from the confirmation of Bacillus anthracis exposure |
| Other severe infections | 20 mg/kg body weight twice daily with a maximum of 750 mg per dose. | According to the type of infections |

Geriatric patients

Geriatric patients should receive a dose selected according to the severity of the infection and the patient's creatinine clearance.

Renal and hepatic impairment

Recommended starting and maintenance doses for patients with impaired renal function:

|  |  |  |
| --- | --- | --- |
| **Creatinine Clearance [mL/min/1.73 m²]** | **Serum Creatinine [μmol/L]** | **Oral Dose [mg]** |
| > 60 | < 124 | See Usual Dosage. |
| 30-60 | 124 to 168 | 250-500 mg every 12 h |
| <30 | > 169 | 250-500 mg every 24 h |
| Patients on haemodialysis | > 169 | 250-500 mg every 24 h (after dialysis) |
| Patients on peritoneal dialysis | > 169 | 250-500 mg every 24 h |

In patients with impaired liver function no dose adjustment is required.

Dosing in children with impaired renal and/or hepatic function has not been studied.

Method of administration

Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice).

In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.

* 1. **Contraindications:**

• Hypersensitivity to the active substance, to other quinolones or to any of the excipients

• Concomitant administration of ciprofloxacin and tizanidine.

**4.4 Special warnings and precautions for use:**

Streptococcal Infections (including Streptococcus pneumoniae)

Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.

Severe infections and mixed infections with Gram-positive and anaerobic pathogens

Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.

Genital tract infections

Epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae isolates.

Ciprofloxacin should be co-adminstered with another appropriate antibacterial agent unless ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded .If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.

Intra-abdominal infections

There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.

Travellers' diarrhoea

The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.

Infections of the bones and joints

Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.

Inhalational anthrax

Use in humans is based on in-vitro susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.

Children and adolescents

The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.

Broncho-pulmonary infections in cystic fibrosis

Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.

Complicated urinary tract infections and pyelonephritis

Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.

Clinical trials have included children and adolescents aged 1-17 years.

Other specific severe infections

Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.

The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.

Hypersensitivity

Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.

Musculoskeletal System

Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.

Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, even within the first 48 hours of treatment. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids. At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.

Ciprofloxacin should be used with caution in patients with myasthenia gravis.

Photosensitivity

Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment.

Central Nervous System

Quinolones are known to trigger seizures or lower the seizure threshold. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued. Psychiatric reactions may occur even after the first administration of ciprofloxacin. In these cases, ciprofloxacin should be discontinued.

Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin. Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition.

Cardiac disorders

Since ciprofloxacin is associated with cases of QT prolongation, caution should be exercised when treating patients at risk for torsades de pointes arrhythmia.

Gastrointestinal System

The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment. In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.

Renal and urinary system

Crystalluria related to the use of ciprofloxacin has been reported. Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.

Hepatobiliary system

Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin. In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.

Glucose-6-phosphate dehydrogenase deficiency

Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.

Resistance

During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by Staphylococcus and Pseudomonas species.

Cytochrome P450

Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, ropinirole, tizanidine). Co-administration of ciprofloxacin and tizanidine is contra-indicated. Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary.

Methotrexate

The concomitant use of ciprofloxacin with methotrexate is not recommended.

Interaction with tests

The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.

**4.5 Interaction with other medicinal products and other forms of interaction:**

Effects of other products on ciprofloxacin:

Chelation Complex Formation

The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer ), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.

Food and Dairy Products

Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.

Probenecid

Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.

Effects of ciprofloxacin on other medicinal products:

Tizanidine

Tizanidine must not be administered together with ciprofloxacin. In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.

Methotrexate

Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended.

Theophylline

Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary.

Other xanthine derivatives

On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.

Phenytoin

Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.

Cyclosporin

A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.

Oral anticoagulants

Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects. There have been many reports of increases in oral anticoagulant activity in patients receiving antibacterial agents, including fluoroquinolones. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of fluoroquinolones to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anticoagulant agent.

Ropinirole

It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of Cmax and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin.

Clozapine

Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after coadministration with ciprofloxacin are advised.

**4.6 Pregnancy and lactation:**

**Pregnancy**

The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus.

As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.

**Breastfeeding**

Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.

**4.7 Effects on ability to drive and use machines**

Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.

**4.8 Undesirable effects:**

The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.

ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **System Organ Class** | **Common**≥ 1/100 to < 1/10 | **Uncommon**≥ 1/1 000 to < 1/100 | **Rare**≥ 1/10 000 to < 1/1 000 | **Very Rare**< 1/10 000` | **Frequency not known**(cannot be estimated from available data) |
| **Infections and Infestations** |  | Mycotic superinfections | Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4) |  |  |
| **Blood and Lymphatic System Disorders** |  | Eosinophilia | Leukopenia  Anaemia  Neutropenia  Leukocytosis  Thrombocytopenia  Thrombocytaemia | Haemolytic  Anaemia  Agranulocytosis  Pancytopenia (lifethreatening)  Bone marrow depression (life threatening) |  |
| **Immune System Disorders** |  |  | Allergic reaction  Allergic oedema / angiooedema | Anaphylactic reaction  Anaphylactic  Shock (lifethreatening)  Serum sickness like reaction |  |
| **Metabolism and Nutrition Disorders** |  | Anorexia | Hyperglycaemia |  |  |
| **Psychiatric Disorders** |  | Psychomotor hyperactivity / agitation | Confusion and disorientation  Anxiety reaction  Abnormal dreams  Depression  Hallucinations | Psychotic Reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide) |  |
| **Nervous System Disorders** |  | Headache  Dizziness  Sleep disorders  Taste disorders | Par- and Dysaesthesia  Hypoaesthesia  Tremor  Seizures  Vertigo | Migraine  Disturbed coordination  Gait disturbance  Olfactory nerve disorders  Intracranial hypertension | Peripheral neuropathy |
| **Eye Disorders** |  |  | Visual disturbances | Visual colour distortions |  |
| **Ear and Labyrinth Disorders** |  |  | Tinnitus,  Hearing loss / Hearing impaired |  |  |
| **Cardiac Disorders** |  |  | Tachycardia |  | Ventricular arrhythmia torsades de pointes\*  QT Prolongation |
| **Vascular Disorders** |  |  | Vasodilatation  Hypotension  Syncope | Vasculitis |  |
| **Respiratory, Thoracic and Mediastinal Disorders** |  |  | Dyspnoea (including asthmatic condition) |  |  |
| **Gastrointestinal Disorders** | Nausea  Diarrhoea | Vomiting  Gastrointestinal and abdominal pains,  Dyspepsia  Flatulence |  | Pancreatitis |  |
| **Hepatobiliary Disorders** |  | Increase in transaminases  Increased bilirubin | Hepatic impairment  Cholestatic icterus  Hepatitis | Liver necrosis (very rarely progressing to life-threatening hepatic failure) |  |
| **Skin and Subcutaneous Tissue Disorders** |  | Rash,  Pruritus  Urticaria | Photosensitivity reactions | Petechiae  Erythema multiforme  Erythema nodosum  Stevens- Johnson Syndrome (potentially lifethreatening)  Toxic epidermal necrolysis (potentially life- threatening) |  |
| **Musculoskeletal, Connective Tissue and Bone Disorders** |  | Musculoskeletal pain (e.g. extremity pain, back pain, chest pain),  Arthralgia | Myalgia,  Arthritis  Increased muscle tone and cramping | Muscular weakness  Tendinitis  Tendon rupture (predominantly  Achilles tendon)  Exacerbation of symptoms of myasthenia gravis |  |
| **Renal and Urinary Disorders** |  | Renal impairment | Renal failure  Haematuria  Crystalluria Tubulointerstitial nephritis |  |  |
| **General Disorders and Administration Site Conditions** |  | Asthenia  Fever | Oedema, Sweating (hyperhidrosis) |  |  |
| **Investigations** |  | Increase in blood alkaline phosphatase | Prothrombin level abnormal Increased amylase |  |  |

\* These events were reported during the postmarketing period and were observed predominantly among patients with further risk factors for QT prolongation.

Paediatric population

The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly.

**4.9 Overdose:**

An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.

Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.

Apart from routine emergency measures it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated.

Only a small quantity of ciprofloxacin (<10%) is eliminated by haemodialysis or peritoneal dialysis.

**5. Pharmacological properties:**

**5.1 Pharmacodynamic properties:**

**Pharmacotherapeutic group:** Fluoroquinolones, **ATC code:** J01MA02

Mechanism of action:

As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.

PK/PD relationship:

Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.

Mechanism of resistance:

In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.

Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in-vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin. Plasmid-mediated resistance encoded by qnr-genes has been reported.

Spectrum of antibacterial activity:

Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:

EUCAST Recommendations

|  |  |  |
| --- | --- | --- |
| **Microorganisms** | **Susceptible** | **Resistant** |
| Enterobacteria | S ≤ 0.5 mg/L | R > 1 mg/ L |
| Pseudomonas | S ≤ 0.5 mg/L | R > 1 mg/ L |
| Acinetobacter | S ≤ 1 mg/L | R > 1 mg/ L |
| Staphylococcus spp.1 | S ≤ 1 mg/L | R >1 mg/L |
| Haemophilus influenzae and Moraxella catarrhalis | S ≤ 0.5 mg/L | R > 0.5 mg/L |
| Neisseria gonorrhoeae | S ≤0.03 mg/L | R > 0.06 mg/L |
| Neisseria meningitidis | S ≤0.03 mg/L | R > 0.06 mg/L |
| Non-species-related breakpoints**\*** | S ≤0.5 mg/L | R > 1 mg/ L |

1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy.

\* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Groupings of relevant species according to ciprofloxacin susceptibility

|  |
| --- |
| **COMMONLY SUSCEPTIBLE SPECIES** |
| Aerobic Gram-positive micro-organisms  Bacillus anthracis (1) |
| Aerobic Gram-negative micro-organisms  Aeromonas spp.  Brucella spp.  Citrobacter koseri  Francisella tularensis  Haemophilus ducreyi  Haemophilus influenzae\*  Legionella spp.  Moraxella catarrhalis\*  Neisseria meningitidis  Pasteurella spp.  Salmonella spp.\*  Shigella spp.\*  Vibrio spp.  Yersinia pestis |
| Anaerobic micro-organisms  Mobiluncus |
| Other micro-organisms  Chlamydia trachomatis ($)  Chlamydia pneumoniae ($)  Mycoplasma hominis ($)  Mycoplasma pneumoniae ($) |
| **SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM** |
| Aerobic Gram-positive micro-organisms  Enterococcus faecalis ($)  Staphylococcus spp. \*(2) |
| Aerobic Gram-negative micro-organisms  Acinetobacter baumannii+  Burkholderia cepacia+\*  Campylobacter spp.+\*  Citrobacter freundii\*  Enterobacter aerogenes  Enterobacter cloacae\*  Escherichia coli\*  Klebsiella oxytoca  Klebsiella pneumoniae\*  Morganella morganii\*  Neisseria gonorrhoeae\*  Proteus mirabilis\*  Proteus vulgaris\*  Providencia spp.  Pseudomonas aeruginosa\*  Pseudomonas fluorescens  Serratia marcescens\* |
| Anaerobic micro-organisms  Peptostreptococcus spp.  Propionibacterium acnes |
| **INHERENTLY RESISTANT ORGANISMS** |
| Aerobic Gram-positive micro-organisms  Actinomyces  Enteroccus faecium  Listeria monocytogenes |
| Aerobic Gram-negative micro-organisms  Stenotrophomonas maltophilia |
| Anaerobic micro-organisms  Excepted as listed above |
| Other micro-organisms  Mycoplasma genitalium  Ureaplasma urealitycum |
| \* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications  + Resistance rate ≥ 50% in one or more EU countries  ($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance  (1): Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on in-vitro susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.  (2): Methicillin-resistant S. aureus very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates. |

**5.2 Pharmacokinetic properties**

Absorption

Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.

Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.

The absolute bioavailability is approximately 70-80%.

A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.

Distribution

Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a nonionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.

Biotransformation

Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display in-vitro antimicrobial activity but to a lower degree than the parent compound.

Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.

Elimination

Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.

|  |  |  |
| --- | --- | --- |
| **Excretion of ciprofloxacin (% of dose)** | | |
|  | **Oral Administration** | |
| **Urine** | **Faeces** |
| Ciprofloxacin | 44.7 | 25.0 |
| Metabolities (M1-M4) | 11.3 | 7.5 |

Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.

Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.

Paediatric patients

The pharmacokinetic data in paediatric patients are limited.

In a study in children Cmax and AUC were not age-dependent (above one year of age). No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.

In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg\*h/L (range 11.8-32.0 mg\*h/L) and 16.5 mg\*h/L (range 11.0-23.8 mg\*h/L) in the respective age groups.

These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.

Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin in-vitro and in animal experiments. This effect was comparable to that of other gyrase inhibitors.

Articular tolerability:

As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.

**6. Pharmaceutical particulars:**

**6.1 List of Excipients:**

The excipients used in the formulation of Ciprofloxacin Tablets USP 500 mg. The list of excipients is as follows:

Microcrystalline Cellulose

Maize Starch

Povidone K-30

Methyl Hydroxybenzoate

Propyl Hydroxybenzoate

Magnesium Stearate

Purified Talc

Croscarmellose Sodium

Kyron T-314

Colloidal Anhydrous Silica

Sodium Starch Glycolate

Hydroxypropyl Methylcellulose-E-15

Instacoat Aqua III (IA-III 40001-White)

**6.2 Incompatibilities:**

Not applicable

**6.3 Shelf life:**

36 months

**6.4 Special precautions for storage:**

Store below 30OC, in a dry place, away from light.

**6.5 Nature and contents of container:**

10 tablets are packed in ALU- PVC Blister. Such 1 ALU- PVC Blisters are packed in printed mono carton of Ciprofloxacin Tablets USP 500 mg. Such 10 mono cartons are packed in outer carton of Ciprofloxacin Tablets USP 500 mg with Patient Information Leaflet.

**6.6 Special precautions for disposal:**

No special requirement.

**7. Applicant:**

**Name and Address of Applicant**

Pushkal Pharmaceutical Limited.

Plot 5, Block 1, Ota Industrial Estate, Ota, Ogun state – Nigeria.

**Name and Address of manufacturer:**

M/s. Bharat Parenterals Limited

Survey No. 144 &146, Jarod Samlaya Road,

Village: Haripura, Ta. Savli, Dist. Vadodara – 391520

Gujarat, INDIA.

Tel.91-2667-251680

Fax: 91-2667-251679

E-mail: ra@bplindia.in